The authors regret that the ‘Conflict of Interest’ section was not included in the original published article. The information is as follows:

Conflict of Interest

RCH reports speaker honoraria from Abbott Diabetes Care, Eli Lilly, Novo-Nordisk, Sanofi-Aventis and Medtronic and advisory board fees from Eli-Lilly, Novo-Nordisk and Abbott Diabetes Care.

K.D. served on advisory boards of Novo Nordisk, Pfizer and Sanofi. K. D. received honoraria for participation in the speaker’s bureau of Abbott, Eli Lilly, Medtronic, Novo.

Nordisk, and Pfizer.

TBI declares speakers’ honoraria from Sanofi, Synlab,Ypsomed, Advisory board participation in Astra Zeneca, Medtronic, Senseonics. He is member of EXPAMED panel of EMA.

LE is funded by NIH 1K23DK121942. She has received consulting fees from Tandem Diabetes Care, and Ypsomed, Speaker fee from Insulet, and research support from Medtronic, Mannkind and JDRF. Her institution has received funding for research grants from Medtronic, Dexcom, Tandem, Insulet, and Beta Bionics.

MT reports heaving received speaker honoraria from Eli Lilly, Novo Nordisk and Medtronic, and advisory board fees from Abbott Diabetes Care.

CM and MM declared no conflict of interest.

The authors would like to apologise for any inconvenience caused.